Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
Public ClinicalTrials.gov record NCT00652626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. The second is to determine the effect renal impairment has or does not have on the absorption of azacitidine. The third is to determine if azacitidine is safe and well tolerated in patients with renal function impairment.
Study identification
- NCT ID
- NCT00652626
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 31 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2008 (Actual)
- Primary completion
- Jul 1, 2012 (Actual)
- Completion
- Jul 1, 2012 (Actual)
- Last update posted
- Nov 19, 2019
2008 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sutter East Bay Hospitals | Berkeley | California | 94704 | — |
| Palm Springs Research Institute | Hialeah | Florida | 33012 | — |
| MCG Cancer Center | Augusta | Georgia | 30912 | — |
| Joliet Oncology-Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| University of Kentucky-Markey Cancer Center Clinical Research Organization | Lexington | Kentucky | 40536 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Mid Dakota Clinical P.C. - Cancer Treatment and Research Center | Bismarck | North Dakota | 58501 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Pharma Resource | East Providence | Rhode Island | 02915 | — |
| Cancer Therapy and Research Center | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00652626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00652626 live on ClinicalTrials.gov.